Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 8/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 8/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 6/20 | 0.44 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.40 |
| ▸ | DHODH | Q02127 | 1/20 | 0.39 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16787517 | 0.79 | ABL1 (0.40) | ABL1 | |
| SCHEMBL20437914 | 0.79 | LCK (0.42) | ABL1 | |
| SCHEMBL20437882 | 0.77 | CYP11B1 (0.47) | ABL1CYP11B2CYP11B1GRIA2DHODH | |
| SCHEMBL26971204 | 0.77 | MAPT (0.44) | — | |
| SCHEMBL3813230 | 0.76 | ABL1 (0.63) | ABL1CYP11B2CYP11B1 | |
| SCHEMBL888893 | 0.75 | CHRNA7 (0.36) | — | |
| SCHEMBL3208265 | 0.74 | ABL1 (0.40) | ABL1 | |
| SCHEMBL12926034 | 0.74 | CYP2A6 (0.56) | CYP11B2CYP11B1CYP17A1 | |
| SCHEMBL22579317 | 0.73 | ESR1 (0.38) | ABL1 | |
| SCHEMBL20437906 | 0.73 | CYP11B1 (0.51) | ABL1CYP11B2CYP11B1GRIA2DHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180215763-A1 | COMPOUNDS AND METHODS FOR CDK8 MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2018-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180215763-A1 | COMPOUNDS AND METHODS FOR CDK8 MODULATION AND INDICATIONS THEREFOR | CDK8, CDK7, CDK18 | ABL1 936/4885CYP11B2 517/4885CYP11B1 426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.